Business Wire

Prioritising Asia-Pacific and Product Innovation for Effective English Language Learning: Novakid Reports Healthy Growth in 1H2022

26.7.2022 09:00:00 EEST | Business Wire | Press release

Share

Novakid, Europe’s leading online English platform for children and an established EdTech company reinventing learning English as a Second Language (ESL), increased its presence in Asia-Pacific and conducted 2.8 M lessons during the first half of 2022.

During 1H2022, Novakid continued to strengthen its positions in 49 markets across the globe. As a result, the company's current client portfolio in Europe accounts for 70%, with Romania as a new growth market in Europe. The MENA region (Middle East and North Africa) accounts for 14% (2pp increase since the end of 2021). The Asia-Pacific countries (Malaysia, Indonesia, Japan and South Korea), now represent almost 16% of the company’s portfolio. The client base in the region has grown twice over compared to the beginning of the year. The most significant results are demonstrated in South Korea (34%) and Japan (78%).

“To operate successfully in the highly competitive international EdTech and ESL markets, businesses need strong diversification strategies, especially in these times of social and economic uncertainty. For this reason, Novakid’s priority for the first half of 2022 was to focus on new growth regions - Hong Kong, Japan and South Korea - where online language learning is driven by the massive digitalization of education over the last few years,” said Dmitry Malin, co-founder and COO of Novakid.

The total number of English lessons conducted on Novakid’s proprietary software since the beginning of 2022 reached 2.8 million, which is 15% higher than the total number of classes delivered during 2021 (2.4 million). At peak times, the platform hosted up to 1,400 lessons simultaneously.

Novakid has increased its teaching staff to nearly 2,700 native English speakers and near-native tutors. The company has continued to improve the qualifications of its teachers by launching a series of webinars and training courses.

The focus during H12022 was the further development of quality and innovative educational content for learning English. Following the release of the first-ever product on the ESL market - Novakid Magic Academy, a story-based, gamified English learning environment - at the end of 2021, Novakid has implemented this curriculum with over 130,000 students of all ages and levels in 6 months.

The Novakid Magic Academy, which forms part of the Novakid Game World, has proven its effectiveness with regards to the learning outcomes of young students: the average learning performance rate is 12% higher after a minimum of four months of lessons, resulting in a 39% better learning performance for students enrolled in the Level I Novakid Magic Academy ESL course. Speech-to-text solutions and emotion recognition software are being developed to make the in-lesson analysis more advanced.

For the second year in a row, Novakid has been included in the annual GSV EdTech top 150 list of the leading private companies in the digital learning space. In March 2022, Novakid was included on the Forbes Top 500 list of America’s Best Startup Employers. Novakid has also been recognised as a finalist in the 2022 EdTech Digest Awards in the category ‘Best Language Learning Solution’.

In June 2022, Novakid was selected as the winner of the “Overall Language Learning Company of the Year” in the 2022 EdTech Breakthrough Awards. Analysts studied the work of more than 80 online schools operating in Europe. The experts assessed the number of active students and their level of satisfaction with the educational process, the level of training and experience of teachers, as well as prices.

“The combination of product expansion and innovation over the past six months has led to impressive growth. We rolled out our new gamified story-based English curriculum - Novakid Game World - to all students during H12022, and can proudly guarantee that the methodology, which is based on engagement, leads students to language proficiency. The results of our young English learners are the biggest achievement for Novakid,” commented Max Azarov, co-founder and CEO of Novakid.

Accelerated by Covid-19, the online ESL industry for both children and adult students is set to continue its growth trajectory for the next few decades. According to the latest research study Online Language Learning Market run by Facts & Factors, the market is predicted to grow to around $28,5 billion by 2028 with a CAGR of around 18,8% during the period 2022 to 2028. At the same time, the K-12 education market is growing at a compound annual growth rate of 31,6% over the next 5 years according to Mordor Intelligence.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Margarita Maltseva
mmaltseva@novakidschool.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Announces First Dose in Phase 3 Study with Enpatoran for Lupus Patients with Active Skin Manifestations30.4.2026 15:05:00 EEST | Press release

Merck, a leading global science and technology company, today announced the first patient was dosed in the Phase 3 program, ELOWEN-1 (NCT07332481) and ELOWEN-2 (NCT07355218), evaluating enpatoran in people living with lupus who experience active skin manifestations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430733656/en/ David Weinreich, Global Head of R&D and Chief Medical Officer “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations,” said David Weinreich, Global Head of R&D, Merck. “With enpatoran, we aim to target the underlying drivers of lupus and redefine how to approach the disease by understanding both visible skin manifestations and systemic activity.” Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor designed to modulate pathways central to lupus-related inflammatio

The LYCRA Company Strengthens Sustainability Leadership, Appoints Alistair Williamson as VP of Product Sustainability30.4.2026 15:00:00 EEST | Press release

The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. In this role, he will guide the company’s next chapter of sustainability strategy and oversee all initiatives aimed at reducing environmental impact across products, operations, and innovation platforms. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260430942396/en/ The LYCRA Company has appointed longtime executive Alistair Williamson as vice president of product sustainability, reaffirming its commitment to developing sustainable solutions for apparel and personal care products. Williamson has four decades of experience in textile fibers and apparel, having held commercial, sales, and marketing leadership roles across EMEA, North America, and South Asia. Before joining the predecessor of The LYCRA Company i

Riskified Announces 2026 Titans of Ecommerce Award Winners30.4.2026 15:00:00 EEST | Press release

Riskified (NYSE: RSKD), a global leader in ecommerce fraud and risk intelligence, today announced the 2026 Titans of Ecommerce Awards, recognizing outstanding ecommerce leaders who are redefining fraud prevention while driving business growth. The winners are: Titan of Americas: Joseph Chin, Senior Director of Revenue Assurance, Michael Kors Joseph Chin has evolved revenue assurance into a strategic lever for growth at Michael Kors. Deeply knowledgeable in fraud and payments, he maintains a hands-on approach, continually collaborating with Riskified to identify innovative opportunities, optimize performance, and pilot new initiatives. Joseph is highly effective at building internal alignment and securing stakeholder buy-in for new strategies. His leadership shone during Cyber Five, where his close collaboration with Riskified and real-time insights delivered one of Michael Kors’ strongest performance periods. Titan of Europe: Ash Cummings, Ecommerce Fraud Prevention Manager, Gymshark A

CorFlow Therapeutics Announces Successful Completion of Phase 1 and First Patients Enrolled in Phase 2 of the MOCA II Pivotal Trial, Approval to Start the REVITALISE RCT in Europe, and Strengthening of Clinical Leadership30.4.2026 14:00:00 EEST | Press release

CorFlow Therapeutics AG (CorFlow), a clinical-stage company focused on transforming the diagnosis and treatment for heart attack patients, today announced multiple milestones in advancing its clinical program and the strengthening of clinical leadership. Phase 1 of the company’s MOCA II FDA Pivotal Trial was successfully reached after safety and performance goals were met with STEMI heart attack patients who had the proprietary PCoFI diagnostic measurement of microvascular obstruction (MVO) made during a stenting procedure, when compared to the reference standard diagnosis by cardiac MRI in the subsequent days. Phase 1 included 19 patients enrolled across 5 US and 3 European sites. MOCA II follows the FIH MOCA I study and primarily aims to validate the threshold value of the proprietary PCoFI measurement for diagnosing MVO in the setting of primary angioplasty compared to cardiac MRI. This milestone achievement, which was confirmed by the study’s independent DSMB (Data and Safety Monit

Agendia to Present New Data Demonstrating the Expanded Clinical Utility of MammaPrint ® and BluePrint ® at the 2026 ESMO Breast Cancer Annual Congress30.4.2026 14:00:00 EEST | Press release

Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new data at the 2026 European Society for Medical Oncology (ESMO) Annual Congress on Breast Cancer, taking place May 6-8 in Berlin, Germany. The company will present two posters featuring data from the prospective FLEX Study and an independent post hoc analysis of the landmark MINDACT trial that underscore the prognostic value of MammaPrint® + BluePrint® in early-stage breast cancer (EBC). Poster #65P | Thursday, May 7, 13:15 – 14:15 p.m. CEST | Presenter: Elena Shagisultanova Prognostic Performance of MammaPrint in Patients with Small T1a, b, and c Node-Negative Early Breast Cancer A retrospective analysis from the FLEX Study involving 4,349 patients highlights the biological heterogeneity within small, node-negative (T1a, b, and c) tumors – a group that typically has favorable outcomes. MammaPrint (MP) identified a High Risk 2 (H2) subset, representing 10% of all patients and 5% of those

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye